Depomed (NASDAQ:DEPO)‘s stock had its “hold” rating restated by analysts at Piper Jaffray Companies in a report released on Thursday. They currently have a $8.00 price objective on the specialty pharmaceutical company’s stock. Piper Jaffray Companies’ price target points to a potential upside of 17.65% from the company’s current price.

Other equities analysts have also issued research reports about the stock. BidaskClub lowered shares of Depomed from a “hold” rating to a “sell” rating in a research report on Tuesday, January 23rd. ValuEngine lowered shares of Depomed from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Mizuho upgraded shares of Depomed from a “neutral” rating to a “buy” rating and set a $9.00 target price for the company in a research report on Tuesday, December 5th. UBS Group increased their target price on shares of Depomed from $6.00 to $7.00 and gave the stock a “neutral” rating in a research report on Friday, November 10th. Finally, Morgan Stanley upgraded shares of Depomed from an “underweight” rating to an “equal weight” rating in a research report on Thursday, November 9th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the company. Depomed currently has an average rating of “Hold” and a consensus target price of $10.14.

How to Become a New Pot Stock Millionaire

Depomed (NASDAQ:DEPO) traded up $0.11 on Thursday, reaching $6.80. 1,730,000 shares of the company traded hands, compared to its average volume of 1,320,000. The company has a market capitalization of $435.21, a price-to-earnings ratio of -5.53 and a beta of 1.10. The company has a debt-to-equity ratio of 2.90, a quick ratio of 0.79 and a current ratio of 0.83. Depomed has a one year low of $4.31 and a one year high of $16.29.

Depomed (NASDAQ:DEPO) last posted its quarterly earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $0.15 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.10 by $0.05. The company had revenue of $94.41 million during the quarter, compared to analyst estimates of $88.75 million. Depomed had a negative net margin of 26.92% and a negative return on equity of 42.87%. equities analysts predict that Depomed will post -0.72 EPS for the current year.

In other Depomed news, insider Arthur J. Higgins bought 75,000 shares of the business’s stock in a transaction on Thursday, December 14th. The stock was purchased at an average price of $8.16 per share, for a total transaction of $612,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.59% of the stock is owned by company insiders.

Large investors have recently modified their holdings of the business. Nationwide Fund Advisors lifted its holdings in shares of Depomed by 1.5% in the second quarter. Nationwide Fund Advisors now owns 35,938 shares of the specialty pharmaceutical company’s stock worth $386,000 after buying an additional 533 shares in the last quarter. Voya Investment Management LLC lifted its holdings in shares of Depomed by 10.4% in the second quarter. Voya Investment Management LLC now owns 29,495 shares of the specialty pharmaceutical company’s stock worth $317,000 after buying an additional 2,790 shares in the last quarter. Alliancebernstein L.P. lifted its holdings in shares of Depomed by 10.6% in the fourth quarter. Alliancebernstein L.P. now owns 79,006 shares of the specialty pharmaceutical company’s stock worth $636,000 after buying an additional 7,560 shares in the last quarter. Alps Advisors Inc. lifted its holdings in shares of Depomed by 12.5% in the fourth quarter. Alps Advisors Inc. now owns 69,769 shares of the specialty pharmaceutical company’s stock worth $562,000 after buying an additional 7,762 shares in the last quarter. Finally, TSP Capital Management Group LLC lifted its holdings in shares of Depomed by 27.1% in the fourth quarter. TSP Capital Management Group LLC now owns 53,025 shares of the specialty pharmaceutical company’s stock worth $427,000 after buying an additional 11,300 shares in the last quarter. Hedge funds and other institutional investors own 92.40% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This news story was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/depomed-depo-given-hold-rating-at-piper-jaffray-companies/1905436.html.

Depomed Company Profile

Depomed, Inc is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl).

Analyst Recommendations for Depomed (NASDAQ:DEPO)

Receive News & Ratings for Depomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed and related companies with MarketBeat.com's FREE daily email newsletter.